Larimar Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Larimar Therapeutics's estimated annual revenue is currently $8.5M per year.
- Larimar Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Larimar Therapeutics has 55 Employees.
- Larimar Therapeutics grew their employee count by 41% last year.
Larimar Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Medical Officer | Reveal Email/Phone |
2 | VP, Bioanalytics & Developability | Reveal Email/Phone |
3 | VP, Clinical Operations | Reveal Email/Phone |
4 | VP, Biometrics and DM | Reveal Email/Phone |
5 | VP Finance & Operations | Reveal Email/Phone |
6 | VP Regulatory Affair And Counsel | Reveal Email/Phone |
7 | VP - Controller | Reveal Email/Phone |
8 | Director IT | Reveal Email/Phone |
9 | Associate Director, Bioanalytical Development | Reveal Email/Phone |
10 | Associate Director Regulatory Quality and Legal Systems and Operations | Reveal Email/Phone |
Larimar Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.6M | 10 | 0% | N/A | N/A |
#2 | $4M | 26 | 13% | N/A | N/A |
#3 | $0.9M | 6 | -14% | N/A | N/A |
#4 | $1.1M | 7 | 0% | N/A | N/A |
#5 | $10.9M | 70 | 3% | N/A | N/A |
#6 | $0.7M | 9 | 29% | N/A | N/A |
#7 | $4M | 26 | -16% | N/A | N/A |
#8 | $1.7M | 11 | 22% | N/A | N/A |
#9 | $7.6M | 49 | 2% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Larimar Therapeutics?
Larimar Therapeutics, Inc. (Nasdaq:LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
keywords:N/A
N/A
Total Funding
55
Number of Employees
$8.5M
Revenue (est)
41%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Larimar Therapeutics News
Larimar (LRMR) has been on a downward spiral lately with significant ... Larimar Therapeutics, Inc. (LRMR) : Free Stock Analysis Report
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases.
BALA CYNWYD, Pa., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its third quarter and year to date September 30, 2021 operating and financi ...
Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results Bala Cynwyd, PA, November 12, 2021 - Larimar Therapeutics, Inc. ("Larimar") (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its third ...
BALA CYNWYD, Pa., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that David Bettoun, PhD, Vice President Discovery & Non-Clinical R&D of La ...
Other Companies in Bala Cynwyd
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.7M | 57 | 36% | N/A |
#2 | $14.8M | 61 | 11% | N/A |
#3 | $15.1M | 62 | 5% | N/A |
#4 | N/A | 64 | 113% | N/A |
#5 | $15.8M | 65 | 3% | N/A |